Tenax Therapeutics (NASDAQ:TENX) Announces Earnings Results

Tenax Therapeutics (NASDAQ:TENX) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.04, FiscalAI reports.

Tenax Therapeutics Stock Performance

NASDAQ TENX traded down $0.18 during trading hours on Thursday, reaching $1.63. The stock had a trading volume of 1,959,451 shares, compared to its average volume of 2,217,301. Tenax Therapeutics has a 52-week low of $1.31 and a 52-week high of $19.40. The stock has a fifty day moving average of $1.83 and a 200 day moving average of $9.89. The stock has a market cap of $60.99 million, a P/E ratio of -1.10 and a beta of 0.99.

Wall Street Analyst Weigh In

Several research firms have recently commented on TENX. Leerink Partners set a $4.00 price objective on shares of Tenax Therapeutics in a research note on Tuesday, August 11th. Guggenheim downgraded Tenax Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, August 31st. Weiss Ratings lowered Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, September 14th. Chardan Capital lowered Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 target price for the company. in a research note on Tuesday, August 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tenax Therapeutics in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Tenax Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $14.00.

Tenax Therapeutics News Summary

Here are the key news stories impacting Tenax Therapeutics this week:

• Positive Sentiment: Tenax reported a third-quarter loss of $0.31 per share, narrower than analysts’ expected loss of $0.35. Read More.
• Positive Sentiment: The company said its analysis of the LEVEL trial identified a potential patient-enrichment strategy that it is incorporating into an amended LEVEL-2 protocol. Tenax also received a Type C meeting with the FDA, providing an opportunity to discuss its development plans. These updates may support the program, though they do not erase the earlier trial setback. Read More.
• Negative Sentiment: Several law firms publicized a securities class action filed on behalf of investors who bought TENX shares between November 13, 2023 and August 7, 2026. The complaint alleges Tenax overstated TNX-103’s clinical prospects while raising capital before the Phase 3 LEVEL trial missed its primary endpoint. The allegations have not been proven; the lead-plaintiff deadline is December 28, 2026. The litigation risk and trial disappointment are potential headwinds for the stock. Read More.

Insider Transactions at Tenax Therapeutics

In other Tenax Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 900,000 shares of Tenax Therapeutics stock in a transaction on Thursday, September 3rd. The stock was bought at an average cost of $1.78 per share, with a total value of $1,602,000.00. Following the transaction, the insider owned 6,524,151 shares of the company’s stock, valued at $11,612,988.78. This represents a 16.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have purchased 3,682,899 shares of company stock worth $6,388,279. Company insiders own 10.81% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.